Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 3
2012 2
2014 2
2015 6
2016 5
2017 5
2018 7
2019 12
2020 8
2021 14
2022 15
2023 11
2024 11
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for kerbrat a
Search for Kerbat A instead (1 results)
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanché JP, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau JP, Pottier C, Nifle C, Collongues N, Kerbrat A; OFSEP Investigators. Jouvenot G, et al. Among authors: kerbrat a. JAMA Neurol. 2024 May 1;81(5):490-498. doi: 10.1001/jamaneurol.2024.0395. JAMA Neurol. 2024. PMID: 38526462 Free PMC article.
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, Labauge P, De Sèze J, Vukusic S, Laplaud DA, Papeix C, Moreau T, Thouvenot E, Defer G, Lebrun-Frénay C, Ciron J, Berger E, Stankoff B, Clavelou P, Maillart E, Heinzlef O, Zéphir H, Ruet A, Casez O, Moulin S, Al-Khedr A, Bourre B, Pelletier J, Magy L, Neau JP, Camdessanché JP, Doghri I, Wahab A, Tchikviladzé M, Labeyrie C, Hankiewicz K, Le Page E, Michel L; as the OFSEP Investigators. Hay M, et al. Among authors: kerbrat a. Neurology. 2024 Oct 22;103(8):e209886. doi: 10.1212/WNL.0000000000209886. Epub 2024 Sep 25. Neurology. 2024. PMID: 39321406
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Benallegue N, et al. Among authors: kerbrat a. JAMA Neurol. 2024 Mar 1;81(3):273-282. doi: 10.1001/jamaneurol.2023.5566. JAMA Neurol. 2024. PMID: 38345791 Free PMC article.
Blood immunophenotyping of multiple sclerosis patients at diagnosis identifies a classical monocyte subset associated to disease evolution.
Rodriguez S, Couloume L, Ferrant J, Vince N, Mandon M, Jean R, Monvoisin C, Leonard S, Le Gallou S, Silva NSB, Bourguiba-Hachemi S, Laplaud D, Garcia A, Casey R, Zephir H, Kerbrat A, Edan G, Lepage E, Thouvenot E, Ruet A, Mathey G, Gourraud PA, Tarte K, Delaloy C, Amé P, Roussel M, Michel L. Rodriguez S, et al. Among authors: kerbrat a. Front Immunol. 2025 Jan 8;15:1494842. doi: 10.3389/fimmu.2024.1494842. eCollection 2024. Front Immunol. 2025. PMID: 39845960 Free PMC article.
Meningitis as an Attack Phenotype of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Aboseif A, Kim NN, Bou G, Nathoo N, Guo Y, Pique J, Kerbrat A, Audoin B, Demortiere S, Bourre B, Ciron J, Chen JJ, Cacciaguerra L, Toledano M, Quek AML, Gombolay G, Marignier R, Hacohen Y, Flanagan EP. Aboseif A, et al. Among authors: kerbrat a. JAMA Neurol. 2025 Jun 16;82(8):871-3. doi: 10.1001/jamaneurol.2025.1774. Online ahead of print. JAMA Neurol. 2025. PMID: 40522676
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y, Kerbrat A, Lebrun-Frenay C, Papeix C, Michel L, Laplaud D, Vukusic S, Maillart E, Cohen M, Audoin B, Marignier R, Collongues N; NOMADMUS Study Group. Demuth S, et al. Among authors: kerbrat a. J Neuroinflammation. 2022 Mar 2;19(1):62. doi: 10.1186/s12974-022-02420-2. J Neuroinflammation. 2022. PMID: 35236386 Free PMC article.
Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure.
Commowick O, Istace A, Kain M, Laurent B, Leray F, Simon M, Pop SC, Girard P, Améli R, Ferré JC, Kerbrat A, Tourdias T, Cervenansky F, Glatard T, Beaumont J, Doyle S, Forbes F, Knight J, Khademi A, Mahbod A, Wang C, McKinley R, Wagner F, Muschelli J, Sweeney E, Roura E, Lladó X, Santos MM, Santos WP, Silva-Filho AG, Tomas-Fernandez X, Urien H, Bloch I, Valverde S, Cabezas M, Vera-Olmos FJ, Malpica N, Guttmann C, Vukusic S, Edan G, Dojat M, Styner M, Warfield SK, Cotton F, Barillot C. Commowick O, et al. Among authors: kerbrat a. Sci Rep. 2018 Sep 12;8(1):13650. doi: 10.1038/s41598-018-31911-7. Sci Rep. 2018. PMID: 30209345 Free PMC article.
93 results